# Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]

> **NCT01109498** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Amsterdam Molecular Therapeutics** · enrollment: 14 (actual)

## Conditions studied

- Familial Lipoprotein Lipase Deficiency

## Interventions

- **GENETIC:** Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
- **DRUG:** Mycophenolate mofetil
- **GENETIC:** Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
- **DRUG:** cyclosporine

## Key facts

- **NCT ID:** NCT01109498
- **Lead sponsor:** Amsterdam Molecular Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-08
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2011-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01109498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01109498, "Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01109498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*